DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. - Wikidata - wikimedia - TriplyDB

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

http://www.wikidata.org/entity/Q33393245

about

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies Emerging treatment options for myelofibrosis: focus on pacritinib Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis Guidelines for the management of myeloproliferative neoplasms Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development Clinical potential of pacritinib in the treatment of myelofibrosis Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis Advances in the management of myelofibrosis The evolving treatment paradigm in myelofibrosis A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis.Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations.Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.The indications for allogeneic stem cell transplantation in myeloid malignancies.Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.Immunomodulatory agents in myelofibrosis.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.Emerging drugs for myelofibrosis.Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.Practical management of patients with myelofibrosis receiving ruxolitinib.Ruxolitinib for myelofibrosis--an update of its clinical effects.Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.Alleviating anemia and thrombocytopenia in myelofibrosis patients.Safety considerations when treating myelofibrosis.Managing patients with myelofibrosis and low platelet counts.Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT

P2860

Q26738514-07C85E51-3B0B-4808-91B1-E9495CE6A051 Q26744113-3E969D26-07F5-44E9-B2A8-A429EB5AD768 Q26745939-4FFEB9ED-1A7E-4B3B-8595-778046044149 Q26750696-774F2167-08B5-4953-9835-CE8DBBB36F74 Q26770330-9486AC00-F984-4B0E-9A9F-F2E226248883 Q26778326-3643D2A7-3BF6-49C8-A34A-F9DC7D9AA536 Q26779947-67667A99-E3C4-4618-97DC-99D16DB94CED Q26796450-6B32599F-06E3-4B5A-A917-EEDAFE431BB2 Q26863610-408FF40D-6AF2-4A8F-AE71-DAA35854CFC5 Q26996258-006C42D3-1638-4F12-A905-A063AD21D987 Q27008072-5E569F55-7DBA-454F-9662-AFA1759E8443 Q27021968-7C0D038A-FA4A-450D-A726-5E82413D9829 Q27342179-DB592BAA-33D1-4404-9590-77988F9511EA Q27853043-AD0B5956-CFB0-48F7-ABFC-44C32F4289A8 Q27853374-130F9EEB-E610-48B4-9492-DDE763D93E8F Q28073296-A669F13A-8DE8-431C-A18E-8F994F004BDB Q30244032-E7015F40-D18D-45BD-9920-13D3ADBD0EAA Q30316611-9E4DEA29-9DF7-4B80-9BC5-B09B9465CE4F Q33400683-1DDBCFEC-52DF-4D69-83E8-66DCCEB7BDA8 Q33401615-CF44D1A5-3106-4120-A31B-0F4F2068C400 Q33402522-96A88CA2-B0E4-4393-80C6-384102ADD91F Q33403735-81A769E3-8FD2-4F45-9637-11E4B611C285 Q33404574-7B350927-D793-40A6-9DC0-918D204B76E8 Q33406238-2E8EE413-5D86-4B74-8CB7-F590F80B01BD Q33406990-2915120A-3B40-466A-803A-74BDB0B19F80 Q33410649-471C2405-BD46-4016-8A9A-C81B1FBEDAB5 Q33411502-AD4DD9AC-6EE8-45E5-AF6B-03958B373D13 Q33417217-2343AE98-8A50-49E3-9D2B-16EFE8B8CE4D Q33419399-5F28AFEE-80DC-47D3-8B47-DAEB6B2CDD5C Q33421108-4EF4A97E-2149-415F-A0FC-67AC6E77A0CF Q33430113-7231C7DE-9B88-4F10-AB74-3BC826D35EDC Q33432285-2EA0644C-C4E5-4265-ADD5-7E9FC492910D Q33432406-2F40C626-6046-491A-8011-33B27E51922B Q33433006-9EB1FC6F-DCD6-49FF-ADAC-190579598B8D Q33435178-5B5DF3B5-A0EC-48CC-AA40-9B063CE69290 Q33439559-B87F4E2E-D76B-47C0-B59E-2EDB2295E7F5 Q33439747-188E2F1F-12F3-4F90-B705-65E0CC26042E Q33441917-297567C1-BFEA-4AF6-BB13-E414A37AE9BE Q33443246-49B6589D-5375-497B-A31D-5462782B22AE Q33556843-1C5D5BA0-854A-4CC1-BB6B-A5CEACD99938

P2860

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

http://www.wikidata.org/entity/Q33393245

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

DIPSS plus: a refined Dynamic ...... count, and transfusion status.

@ast

DIPSS plus: a refined Dynamic ...... count, and transfusion status.

@en

type

label

DIPSS plus: a refined Dynamic ...... count, and transfusion status.

@ast

DIPSS plus: a refined Dynamic ...... count, and transfusion status.

@en

prefLabel

DIPSS plus: a refined Dynamic ...... count, and transfusion status.

@ast

DIPSS plus: a refined Dynamic ...... count, and transfusion status.

@en

P1433

Q33393245-F815F254-99A7-470C-8DD7-A757935E09EA

P1476

Q33393245-D4E45CC4-6FCF-4FB8-A05E-0E1619F4BC1C

P2093

Q33393245-2185C6E5-0EB5-4036-BA46-DA6CF5AD9996

Q33393245-2B670ADF-E2DD-4276-BF99-A81A5BA1DB62

Q33393245-413296DD-4B37-456F-A4EE-931E0FE0EB81

Q33393245-4E980AC2-6C63-4CD9-A9D1-D71C5BCC6890

Q33393245-512C3EB0-52FD-4C2C-9724-068270EC4B53

Q33393245-5C74048C-55B1-4E55-9AB1-DB78365985EC

Q33393245-897A9ED2-650B-4337-85FA-1BF73DEB7304

Q33393245-8F4EC8BA-CDE2-49F6-B84C-30A9A5249143

Q33393245-968EB555-BA03-4D7F-B86A-E7AF48E2CDB9

Q33393245-9F3261D9-8706-4A9E-9EF7-7912048D8495

P304

Q33393245-A2152EDB-212F-4AEF-8106-C2B247D3617A

P31

Q33393245-EBF0F753-BAB8-4F50-9090-69C36EBE7861

P356

Q33393245-F000F997-4C70-4FC0-860F-0E1636D7C75E

P407

Q33393245-C8CC9809-8F24-4B27-BD51-45617F937A7E

P433

Q33393245-58ED1F97-06F8-493D-8D0B-3F70AF382787

P478

Q33393245-EFBF1C0B-E153-474B-AF5B-679C9358E967

P50

Q33393245-56D8C616-1608-4911-B431-17022611E532

Q33393245-A71F191B-D904-4D4C-8217-015B3E951E45

P577

Q33393245-CF2ECFD0-B528-4F7F-BEA6-06C8DBBA5C93

P698

Q33393245-8240474F-345D-4E8B-A51A-FD055A5359B4

P921

Q33393245-017F52C3-7E8C-486B-AC28-74A5EAEB6BEF

P356

JCO.2010.32.2446

P1433

Journal of Clinical Oncology

P1476

DIPSS plus: a refined Dynamic ...... count, and transfusion status.

@en

P2093

Animesh Pardanani

http://www.w3.org/2001/XMLSchema#string

Curtis Hanson

http://www.w3.org/2001/XMLSchema#string

Daniel Van Dyke

http://www.w3.org/2001/XMLSchema#string

Domenica Caramazza

http://www.w3.org/2001/XMLSchema#string

Francisco Cervantes

http://www.w3.org/2001/XMLSchema#string

Geeta George

http://www.w3.org/2001/XMLSchema#string

Kebede Begna

http://www.w3.org/2001/XMLSchema#string

Naseema Gangat

http://www.w3.org/2001/XMLSchema#string

Rakhee Vaidya

http://www.w3.org/2001/XMLSchema#string

Susan Schwager

http://www.w3.org/2001/XMLSchema#string

P304

392-397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.32.2446

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Passamonti

P577

2010-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21149668

http://www.w3.org/2001/XMLSchema#string

P921